Prostate cancer drug interaction study aims to improve safety
NCT ID NCT02592317
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This study looks at how the experimental drug JNJ-56021927 changes the way the body processes several common medications in men with castration-resistant prostate cancer. About 23 participants will receive the cancer drug along with a cocktail of other drugs to measure how their levels change in the blood. The goal is to understand potential interactions so doctors can prescribe safer combinations in the future.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Study site
Chisinau, Moldova
-
Study site
Barcelona, Spain
-
Study site
Seville, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new daily pill slow advanced prostate cancer?
- Radiation plus hormone therapy may slow resistant prostate cancer
- Real-World data may reveal Pluvicto's true impact on advanced prostate cancer survival
- Mapping the next steps: how men with advanced prostate cancer are treated after standard therapies fail
- Massive data dive aims to uncover best prostate cancer treatments in real life
- New pill aims to shrink Hard-to-Treat cancers